EMA: Multiple COVID-19 Booster Programs ‘Not Sustainable’ In Long Term
Agency Sees No Evidence Of Vaccine Risk In Pregnancy
Executive Summary
Global regulators have been discussing how best to approach vaccination in the face of possible future coronavirus variants, and whether bivalent or multivalent vaccines could be the answer.
You may also be interested in...
Coronavirus Notebook: Australia OKs Paxlovid, Lagevrio & Nuvaxovid, New Sputnik Data Show ‘Strong Protection’ Against Omicron
International regulators have broadened their discussions on the possible use of bivalent and multivalent vaccines, and the French presidency of the Council of the EU has called for “international solidarity” on vaccine provision.
EMA Head Calls For New Global Workshop On Variant Vaccines
Five vaccines and six therapeutics are now available for use against COVID-19 in the EU, but as Omicron shows, there is likely to be a need for new kinds of vaccines against future virus variants.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.